

HCV infection and clearance in relation to atherosclerosis and metabolic syndrome in an Egyptian village

Thesis submitted for partial fulfillment of M.D. in Public Health

By

Aya Mostafa Kamal EIDin

**Assistant Lecturer, Department of Community Medicine,
Environmental and Occupational Medicine
Faculty of Medicine, Ain Shams University**

Supervised by

Prof. Dr. Sawsan Mohamed El-Ghazali

**Professor of Public Health and Behavioral Medicine
Head of the Department of Community, Environmental and Occupational Medicine
Director of Behavioral Medicine Unit
Faculty of Medicine, Ain Shams University**

Prof. Dr. Mubarak Mohamed Hussein

**Professor of Tropical Medicine
Department of Tropical Medicine
Faculty of Medicine, Ain Shams University**

Prof. Dr. Mostafa El-Hosseiny Mostafa

**Professor of Community Medicine, Environmental and Occupational Medicine
Faculty of Medicine, Ain Shams University**

**Faculty of Medicine
Ain Shams University**

2011

العلاقة بين العدوى والتخلص من الفيروس الكبدى سى و تصلب الشرايين و متلازمة الأيض الغذائى فى قرية مصرية

رسالة مقدمة إيفاء جزئيا للحصول على درجة الدكتوراة فى الصحة العامة

مقدمة من

الطبيبة/ آية مصطفى كمال الدين
المدرس المساعد بقسم طب المجتمع والبيئة و طب الصناعات
كلية الطب - جامعة عين شمس

تحت إشراف

الأستاذ الدكتور/ سوسن محمد الغزالى
أستاذ الصحة العامة و الطب السلوكى و مدير وحدة الطب السلوكى
رئيس قسم طب المجتمع والبيئة و طب الصناعات
كلية الطب - جامعة عين شمس

الأستاذ الدكتور/ مبارك محمد حسين
أستاذ بقسم طب الأمراض المتوطنة
كلية الطب - جامعة عين شمس

الأستاذ الدكتور/ مصطفى الحسينى مصطفى
أستاذ بقسم طب المجتمع والبيئة و طب الصناعات
كلية الطب - جامعة عين شمس

كلية الطب
جامعة عين شمس

2011

LIST OF ABBREVIATIONS

AACE	American Association of Clinical Endocrinologists
ACE	American College of Endocrinology
ALT	Alanine Aminotransferase
ANOVA	Analysis of Variance
AST	Aspartate Aminotransferase
AUC	Area Under the Curve
BMI	Body Mass Index
CAD	Coronary Artery Disease
CDC	Centers for Disease Control and Prevention
CHC	Chronic Hepatitis C infection
CI	Confidence Intervals
CRP	C-Reactive Protein
CVD	Cardiovascular Disease
DBP	Diastolic Blood Pressure
ECG	Electrocardiography
EGIR	European Group for the Study of Insulin Resistance
EIA	Enzyme-linked Immunosorbent Assay
GGT	Gamma Glutamyl transpeptidase
HAV	Hepatitis A Virus
HBsAg	Hepatitis B Surface Antigen
HBV	Hepatitis B Virus
HCADS	Hepatitis C associated Syndrome
HCC	Hepatocellular Carcinoma
HCV	Heptitis C Virus
HDL	High Density Lipoprotein
HIV	Human Immunodeficiency Virus
HOMA	Homeostasis Assessment Model
HTN	Hypertension
ICD	International Classification of Diseases
ID	Identification number
IDF	International Diabetes Federation
IFN	Interferon
IL	Interleukin
IMT	Intima-Media Thickness
IR	Incidence Rate
IR	Insulin Resistance
ISI	Insulin Sensitivity Index
IQR	Interquartile Range

IV	Intravenous
IVGTT	Intravenous glucose tolerance test
LDL	Low Density Lipoprotein
MHz	Megahertz
mmHg	millimeter mercury
mmol/l	millimol per liter
MOHP	Ministry of Health and Population
µg/min	microgram per minute
µm	Micrometer
N	Number
NAFLD	Non Alcoholic Fatty Liver Disease
NASH	Non Alcoholic Steatohepatitis
NCEP-ATPIII	National Cholesterol Education Program-Adult Treatment Panel III
NHTMRI	National Hepatology and Tropical Medicine Research Institute
NHLBI	National Heart, Lung, and Blood Institute
NIH	National Institutes of Health
NS	Non Structural region of the genome
OR	Odds Ratio
PAN	Polyarteritis Nodosa
PWV	Pulse-Wave Velocity
PY	Person Years of observation
QUICKI	Quantitative insulin-sensitivity check index
RNA	Ribonucleic Acid
ROS	Reactive Oxygen Species
RR	Relative Risk
RT-PCR	Real Time Polymerase Chain Reaction
SBP	Systolic Blood Pressure
SD	Standard Deviation
Si	Insulin Sensitivity
SOCS	Suppressor of Cytokine Signaling Proteins
SPSS	Statistical Program for Social Sciences
SVR	Sustained Virological Response
T2D	Type II Diabetes
TG	Triglycerides
TGF-β	Tumour Growth Factor beta
TNF	Tumour Necrosis Factor
VLDL	Very Low Density Lipoprotein
WHO	World Health Organization

LIST OF FIGURES

A) Figures in Review of Literature:		
Figure (1)	Estimated global prevalence of HCV infection	6
Figure (2)	Global distribution of HCV genotypes	9
Figure (3)	Schematic diagram of HCV genome	10
Figure (4)	Course of HCV infection	14
Figure (5)	Stepwise surveillance of cardiovascular disease risk factors among ages 14-64 in Arab countries in 2004	21
Figure (6)	Estimated age-standardized death rate of cardio-vascular disease	22
Figure (7)	The process of atherogenesis	25
Figure (8)	Intima-media thickness	27
Figure (9)	Mechanisms by which microbes induce atherosclerosis	30
Figure (10)	Effects of the metabolic syndrome on different organs	48
Figure (11)	Mechanisms involved in the diabetogenic action of HCV	65
Figure (12)	Overview of the complex interplay between obesity, inflammation, and metabolic syndrome	77
Figure (13)	Molecular Pathways Leading to HCV-Induced Insulin Resistance, Fibrosis, Apoptosis, and Fatty Liver	83
Figure (14)	HCV prevalence by geographical area showing the study site in the Nile Delta	86
Figure (15)	Tanita Body Composition Analyser TBF-300	102

Figure (16)	Diagram of forearm venous occlusion plethysmography	107
B) Figures in Results:		
Figure (17)	Carotid intima-media thickness difference between study groups comparing males to females	132
Figure (18)	Carotid intima-media thickness difference among the study groups comparing different age groups	136
Figure (19)	Comparison of the carotid intima-media thickness levels between centrally obese to those who were not, among the study groups according to age group	137
Figure (20)	Correlation between intima-media thickness and systolic blood pressure in subjects with chronic Hepatitis C	138
Figure (21)	Prevalence of Metabolic Syndrome and its components in males and females	141
Figure (22)	Metabolic syndrome prevalence among the study groups according to age	142
Figure (23)	Metabolic syndrome prevalence according to central obesity and age among the study groups	143
Figure (24)	Metabolic syndrome prevalence according to body mass index and age among the study groups	144
Figure (25)	Prevalence of Pre-diabetes and Diabetes in the study groups	148

CONTENTS

List of Tables	IV
List of Figures	VI
List of Abbreviations	VIII
Introduction	1
Objectives	4
Review of Literature	
<i>I. Hepatitis C Virus Infection</i>	5
- <i>Magnitude of HCV infection</i>	5
- <i>Genotypes</i>	9
- <i>The virus and its life cycle</i>	10
- <i>Modes of transmission</i>	11
- <i>Pathogenesis</i>	13
- <i>Burden of HCV infection</i>	17
- <i>Extrahepatic manifestations</i>	18
<i>II. Hepatitis C and Atherosclerosis</i>	20
- <i>Definition and epidemiology</i>	20
- <i>Risk factors of atherosclerosis</i>	23
- <i>Hypothesis of atherogenesis</i>	24
- <i>Carotid artery intima-media thickness</i>	26
- <i>Diagnostic studies for carotid atherosclerosis</i>	28
- <i>Interrelationship between infectious and chronic disease</i>	28
- <i>Role of hepatitis viruses in atherogenesis</i>	31
- <i>Molecular mechanisms between HCV infection, atherosclerosis and cardiovascular disease</i>	
<i>III. Hepatitis C and the Metabolic Syndrome</i>	33
- <i>Definitions of the metabolic syndrome</i>	33
- <i>Epidemiology of the metabolic syndrome</i>	41
- <i>The association between HCV infection and the metabolic syndrome:</i>	47
<i>HCV infection and Obesity</i>	49
<i>HCV infection and Lipid metabolism</i>	50
<i>HCV infection, Insulin resistance, and Diabetes</i>	52
- <i>HCV infection and hypertension</i>	66
- <i>Metabolic syndrome Definitions and Cardiovascular Disease Risk Prediction</i>	67
- <i>Molecular mechanisms in HCV infection leading to metabolic syndrome and atherosclerosis</i>	71

Subjects and methods	86
Results	118
Discussion	161
Conclusion	182
Recommendations	183
Summary	186
References	190
Appendices	
- <i>Protocol</i>	A
- <i>Questionnaire</i>	B
- <i>Anthropometry sheet</i>	C
- <i>Clinical examination sheet</i>	D
- <i>Bioimpedence sheet</i>	E
- <i>Abdominal ultrasound sheet</i>	F
- <i>Carotid IMT-femoral PWV sheet</i>	G
- <i>IVGTT/Plethysmography</i>	H
- <i>Published paper</i>	I
Arabic Summary	

LIST OF TABLES

A) Tables in Review of Literature:		
Table (I)	Prevalence of HCV infection by countries	7
Table (II)	Diagnosis of type 2 Diabetes	35
Table(III)	Prevalence of type 2 diabetes in chronic hepatitis subjects	58
Table (IV)	Prevalence of type 2 diabetes HCV- and non-HCV related chronic liver diseases	58
Table (V)	Prevalence of type 2 diabetes in cirrhosis	62
Table (VI)	Definitions of terms used in the analysis	114
Table (VII)	Upper limits of various biological measurements carried out in this study	116
B) Tables in Results:		
Table (1)	Response rates among groups of the study	118
Table (2)	Comparison of the socio-demographic characteristics between responders and non-responders	119
Table (3)	Sociodemographic characteristics of responders among the three study groups	121
Table (4)	Anthropometric and blood pressure measurements among the study groups	123
Table (5)	Risk factors of Hepatitis C infection among the study groups	124
Table (6)	Signs and symptoms suggestive of liver disease among the study groups	125
Table (7)	Biochemical Liver profile among the study groups	126
Table (8)	Glucose and lipid profiles among the study groups	127
Table (9)	Family history of diabetes, hyperlipidemia, stroke, and myocardial infarction among the study groups	128
Table (10)	Risk factors for atherosclerosis and cardiovascular disease among study groups	129

List of Tables

Table (11)	Carotid intima-media thickness results among the study groups	132
Table (12)	Correlation coefficients between intima-media thickness and risk factors in cleared HCV infection and chronic HCV infection study groups	134
Table (13)	Personal history suggestive of cardiovascular disease among the study groups	139
Table (14)	Components contributing to the metabolic syndrome among the study groups according to the NCETP-ATPIII	140
Table (15)	Measurements of Obesity and Bioimpedence among the study groups	145
Table (16)	Measurements of visceral abdominal fat by ultrasound among the study groups	147
Table (17)	Comparison of those who travelled to Cairo to complete the main study procedures and those who did not regarding socio-demographic characteristics, study groups, and medical conditions	150
Table (18)	Inflammatory markers associated with metabolic syndrome among the study groups	151
Table (19)	Kidney functions among the study groups	152
Table (20)	Comparison of participants of the Sub Study procedures to no-participants regarding socio-demographic characteristics, study groups, and medical conditions	153
Table (21)	Results of the Intra venous glucose tolerance test (IVGTT) among the study groups	155
Table (22)	Results of Plethysmography among the study groups	157
Table (23)	Odds ratios for metabolic syndrome and other medical conditions by regression analysis in those who cleared HCV infection	158
Table (24)	Odds ratios for metabolic syndrome and other medical conditions by regression analysis in those with chronic HCV infection	159

Hepatitis C virus infection and clearance in relation to atherosclerosis and metabolic syndrome in an Egyptian village

INTRODUCTION:

The developing countries face the twin burden of escalating non-communicable disease and declining, but still prevalent, infectious disease. Egypt has the highest hepatitis C virus (HCV) prevalence in the world (overall prevalence of HCV antibody is 12% in the general population, reaching 40% in persons over age 40 in rural areas) ¹, and a population which is prone to diabetes and cardio-vascular disease (CVD).

A causal link between infection and CVD has been proposed but its mechanism is still unclear ². Pathogens could plausibly promote the development of atherosclerosis in a number of ways, including pro-inflammatory and pro-thrombotic effects, and disturbances of lipid metabolism ^{3,4}. Whether hepatitis C increases CVD risk is uncertain. HCV infection is associated with increased common carotid IMT and carotid-artery plaques in some ^{5,6}, but not all studies ^{7,8}.

Discrepancies between studies are likely to be due to inadequacies in study design; for example, the numbers of individuals infected with hepatitis C have often been small ⁹, some combined hepatitis C and hepatitis B ¹⁰, while in others comparator groups could be hospital based ⁶ which may bias the relationship between atherosclerosis and HCV.

Also, HCV infection in population based studies is associated with a 3.5 fold increased prevalence, and an 11 fold increased incidence of diabetes ^{9,10}. HCV positive individuals appear more insulin resistant than non infected controls ¹¹. The mechanism of this association is unclear. Diabetes could be the consequence of inflammatory or autoimmune responses to hepatitis. The enhanced risk of atherosclerosis in diabetes, in part at least, is attributed to the classical dyslipidaemic pattern of insulin resistance. This consists of elevations in circulating triglyceride, and a reduction in HDL cholesterol levels ¹². But an anomaly presents itself in HCV. Lipid and lipoprotein abnormalities in HCV are characterised by **hypocholesterolaemia** and **hypo-betalipoproteinaemia**, i.e. reduced levels of apolipoprotein B

(apoB)-containing lipoproteins, such as LDL and VLDL cholesterol¹³. Superficially, in terms of atherosclerotic risk, this circulating lipoprotein pattern would be viewed as favourable, and runs directly counter to observations in the classical manifestations of the metabolic syndrome¹⁴.

The proposed study will inform understanding of the links between infectious and CVD, the mechanisms and impact of the discordant effects of hepatitis C on glucose tolerance and lipid metabolism, and how this relates to atherosclerotic risk. This study will further our knowledge of the metabolic syndrome, as people with chronic hepatitis C infection appear to show a breakdown in the natural association between diabetes and dyslipidaemia providing valuable insights into the mechanisms of insulin resistance and its sequelae, and indicators for prevention, for all populations. Finally, clearance of infection appears to reverse some of the metabolic changes described above. It is unclear what the impact of such reversal will be on atherosclerotic risk, but is an important public health question.

OBJECTIVES:

1. To determine the association of HCV infection and atherosclerosis
2. To identify the relationship between HCV infection and metabolic syndrome

SUBJECTS AND METHODS:

Study design

Analytical multiple community based cross-sectional studies within the ongoing Zawyat Razin village cohort study.

Study subjects

Participants will be recruited from cohort adults aged over 35 from three main groups: chronically infected with HCV (positive anti-HCV antibodies and positive RNA); cleared HCV infection (positive anti-HCV antibodies and negative RNA), and never infected (negative anti-HCV antibodies). Hepatitis B antigen positive individuals will be excluded.

Ethical consideration

The study protocol is approved by the MOHP Institutional Review Board and a local ethics committee set up for hepatitis studies in Egypt. Participants will be provided by documented informed consent

Study sample

Sampling will be stratified by gender and 5 year age group
